Corrigendum to "Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms" [Gynecol. Oncol. 102 (2006) 5-7] (DOI:10.1016/j.ygyno.2006.03.048);Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms

Gynecologic Oncology

Volumn 102, Issue 1, 2006, Pages 5-7

  Bidus, Michael A ^a,b   Webb, Joel C ^a,b   Seidman, Jeffrey D ^b   Rose, G Scott ^a,b   Boice, Charles R ^b   Elkas, John C ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Bevacizumab; Borderline; Low malignant potential; Micropapillary; Ovarian cancer; Serous; VEGF; Well differentiated

Indexed keywords

2 METHOXYESTRADIOL; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ANASTROZOLE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; IMATINIB; NAVELBINE; PACLITAXEL; TAMOXIFEN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE PAIN; CASE REPORT; DISEASE EXACERBATION; DOSE RESPONSE; ENDOMETRIOID CARCINOMA; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; LONG TERM CARE; MYALGIA; OSTEOARTHRITIS; OVARY TUMOR; PERITONEUM CANCER; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; SOLID TUMOR; TREATMENT DURATION;

EID: 33744911102     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.09.010     Document Type: Erratum

References (15)

1. Rini B. VEGF-targeted therapy in metastatic renal cell carcinoma. Oncologist 10 (2005) 191-197
2. Monk B.J., Choi D.C., Pugmire G., and Burger R.A. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 96 3 (2005 (Mar)) 902-905
3. Brustmann H., and Naude S. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage. Gynecol Oncol 84 1 (2002 (Jan)) 47-52
4. Seidman J.D., and Kurman R.J. Treatment of micropapillary serous ovarian carcinoma (the aggressive variant of serous borderline tumors). Cancer 95 4 (2002) 675-676
5. Bristow R.E., Gossett D.R., Shook D.R., Zahurak M.L., Tomacruz R.S., Armstrong D.K., et al. Micropapillary serous ovarian carcinoma: surgical management and clinical outcome. Gynecol Oncol 86 (2002) 163-170
6. Sehdev A., Sehdev P.S., and Kurman R.J. Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. Am J Surg Pathol 27 6 (2003) 725-736
7. Sherman M.E., Mink P.J., Curtis R., Cote T.R., Brooks S., Hartge P., et al. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 100 5 (2004) 1045-1052
8. Crispens M.A., Bodurka D., Deavers M., Lu K., Silva E.G., and Gershenson D.M. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 99 1 (2002) 3-10
9. Pettersson F. Annual report on the results of treatment in gynecological cancer. International Federation of Gynecology and Obstetrics vol. 20 (1988), Panorama A.B. Press, Stockholm 110
10. Shimizu Y., Kamoi S., Amada S., Hasumi K., Akiyama F., and Silverberg S.G. Toward the development of a universal grading system for ovarian epithelial carcinoma: I. Prognostic significance of histopathologic features-Problems involved in the architectural grading system. Gynecol Oncol 70 1 (1998) 2-12
11. Shimizu Y., Kamoi S., Amada S., Akiyama F., and Silverberg S.G. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 82 5 (1998) 893-901
12. Ishioka S., Sagae S., Terasawa K., Sugimura M., Nishioka Y., Tsukada K., et al. Comparison of the usefulness between a new universal grading system for epithelial ovarian cancer and the FIGO grading system. Gynecol Oncol 89 3 (2003) 447-452
13. Sato Y., Shimamoto T., Amada S., Asada Y., and Hayashi T. Prognostic value of histologic grading of ovarian carcinoma. Int J Gynecol Pathol 22 1 (2003) 52-56
14. Meinhold-Heerlein I., Bauerscglag D., Hilpert F., Dimitrov P., Sapinoso L.M., Orlowska-Volk M., et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24 (2005) 1053-1065
15. Esquin D., Kline E.R., and Giannakakou P. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res 65 19 (2005) 9021-9028